Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBT Margin (2016 - 2025)

Anaptysbio filings provide 10 years of EBT Margin readings, the most recent being 83.68% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 17140.0% year-over-year to 83.68%, compared with a TTM value of 67.74% through Sep 2025, down 6282.0%, and an annual FY2024 reading of 159.25%, down 15900.0% over the prior year.
  • EBT Margin hit 83.68% in Q4 2025 for Anaptysbio, up from 30.23% in the prior quarter.
  • The five-year high for EBT Margin was 1347.75% in Q4 2023, with the low at 3237.84% in Q1 2022.
  • Median EBT Margin over the past 5 years was 322.11% (2024), compared with a mean of 833.25%.
  • The sharpest move saw EBT Margin crashed -313115bps in 2021, then skyrocketed 263239bps in 2022.
  • Year by year, EBT Margin stood at 3075.07% in 2021, then surged by 86bps to 442.68% in 2022, then skyrocketed by 404bps to 1347.75% in 2023, then tumbled by -107bps to 87.72% in 2024, then soared by 195bps to 83.68% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 83.68%, 30.23%, and 173.34% for Q4 2025, Q3 2025, and Q2 2025 respectively.